Preclinical studies on various pancreatic cancer mouse models demonstrated that KRAS G12D siRNA could be effectively transferred to the tumor site, induce prominent regression in tumor size, and prolong survival, holding remarkable potential for PDAC treatment (43, 45). Here, KRAS is linked to pancreatic neoplasm.